Robert Owen Dillman

Summary

Affiliation: Hoag Cancer Center
Country: USA

Publications

  1. ncbi request reprint Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:570-80. 2004
  2. ncbi request reprint International Society for Biological Therapy for Cancer: 20th anniversary
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    J Immunother 28:169-74. 2005
  3. ncbi request reprint Lymphocyte therapy of renal cell carcinoma
    Robert O Dillman
    Hoag Comprehensive Cancer Center, Newport Beach, CA 92658, USA
    Expert Rev Anticancer Ther 5:1041-51. 2005
  4. ncbi request reprint Patient-specific dendritic-cell vaccines for metastatic melanoma
    Robert O Dillman
    N Engl J Med 355:1179-81. 2006
  5. doi request reprint Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines
    Robert O Dillman
    Hoag Cancer Institute One Hoag Drive, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 26:407-15. 2011
  6. pmc Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
    R O Dillman
    Medical and Scientific Director, Hoag Cancer Center, Newport Beach, CA 92658, USA
    Clin Exp Med 6:1-12. 2006
  7. ncbi request reprint High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Am J Clin Oncol 28:281-8. 2005
  8. ncbi request reprint Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:730-7. 2004
  9. ncbi request reprint Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:658-65. 2004
  10. ncbi request reprint Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:581-8. 2004

Collaborators

Detail Information

Publications57

  1. ncbi request reprint Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:570-80. 2004
    ..In this study, we report the final clinical results and efforts to define vaccine potency on the basis of clinical outcome for these 25 patients with advanced renal cell carcinoma...
  2. ncbi request reprint International Society for Biological Therapy for Cancer: 20th anniversary
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    J Immunother 28:169-74. 2005
  3. ncbi request reprint Lymphocyte therapy of renal cell carcinoma
    Robert O Dillman
    Hoag Comprehensive Cancer Center, Newport Beach, CA 92658, USA
    Expert Rev Anticancer Ther 5:1041-51. 2005
    ..More recently, allogeneic immune therapy using nonmyeloablative hematopoietic stem cell transplant and/or donor lymphocyte therapy has also shown promise...
  4. ncbi request reprint Patient-specific dendritic-cell vaccines for metastatic melanoma
    Robert O Dillman
    N Engl J Med 355:1179-81. 2006
  5. doi request reprint Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines
    Robert O Dillman
    Hoag Cancer Institute One Hoag Drive, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 26:407-15. 2011
    ..Dependencies between variables were common, but these multivariate linear models yielded high classification accuracy for survival at 3.5 years and identified two features of the vaccine itself as being of independent significance...
  6. pmc Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
    R O Dillman
    Medical and Scientific Director, Hoag Cancer Center, Newport Beach, CA 92658, USA
    Clin Exp Med 6:1-12. 2006
    ..These products have been underutilised because of the complexity of treatment coordination and concerns regarding reimbursement...
  7. ncbi request reprint High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Am J Clin Oncol 28:281-8. 2005
    ..010). As a group, patients with distant metastatic breast cancer who underwent tandem transplants had a better posttransplant survival than patients who underwent a single HDC...
  8. ncbi request reprint Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:730-7. 2004
    ..The potential for therapeutic use of tumor-infiltrating lymphocytes (TIL), as adoptive cellular therapy has been touted for many years with some encouraging reports in patients with metastatic melanoma...
  9. ncbi request reprint Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:658-65. 2004
    ..The aim of this study was to investigate the feasibility, safety, and clinical efficacy of patient-specific dendritic cell vaccines in patients with metastatic melanoma. A planned interim analysis was conducted on the first 20 patients...
  10. ncbi request reprint Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas
    Robert Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:581-8. 2004
    ..We attempted to determine the feasibility, safety, and clinical effects of autologous tumor vaccine-derived sarcomas...
  11. ncbi request reprint Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California, USA
    J Immunother 27:398-404. 2004
    ..The median survival rates are higher than reported in most published series of patients who underwent reoperation for recurrent GBM. A randomized trial would be needed to establish therapeutic benefit...
  12. ncbi request reprint Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 21:130-7. 2006
    ..We conducted a phase II trial in metastatic renal cell cancer of outpatient subcutaneous (s.c.) interferon-alpha2b (IFN), followed by an inpatient hybrid schedule of bolus and continuous interleukin-2 (IL- 2)...
  13. ncbi request reprint Improving survival for patients with breast cancer compared with intramural and extramural benchmarks
    Robert O Dillman
    Department of Clinical and Laboratory Cancer Research, Hoag Cancer Center, Hoag Hospital, Newport Beach, CA 92658, USA
    Clin Breast Cancer 7:480-5. 2007
    ..Advances in the early detection and treatment of breast cancer during the past 20 years should have been associated with increased survival...
  14. doi request reprint Cancer immunotherapy
    Robert O Dillman
    Hoag Cancer Institute of Hoag Hospital, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 26:1-64. 2011
    ..As the fourth modality of cancer treatment, biotherapy/immunotherapy is an increasingly important component of the anticancer armamentarium...
  15. doi request reprint Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 25:553-7. 2010
    ..This is the first time she has been in a complete remission since her initial diagnosis. Patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases...
  16. doi request reprint Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer
    Robert O Dillman
    Hoag Cancer Center, Department of Medical Oncology, Hoag Memorial Hospital Presbyterian, Newport Beach, CA 92658, USA
    Int J Radiat Oncol Biol Phys 79:719-23. 2011
    ..Postoperative radiation therapy may benefit patients who have organ-confined prostate cancer with positive margins...
  17. doi request reprint Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma
    Robert Owen Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    J Immunother 32:914-9. 2009
    ..Intralesional LAK cell therapy is safe and the survival sufficiently encouraging to warrant further evaluation in a randomized phase 2 trial of intralesional therapies with LAK or carmustine-impregnated wafers...
  18. doi request reprint Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 24:311-9. 2009
    ..016). This patient-specific vaccine warrants further investigation, based on its safety and encouraging survival rates. (Clinical Trial Number: NCI-V01-1646)...
  19. doi request reprint Surgical resection and long-term survival for octogenarians who undergo surgery for non-small-cell lung cancer
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92648, USA
    Clin Lung Cancer 10:130-4. 2009
    ..An increasing proportion of newly diagnosed non-small-cell lung cancer (NSCLC) patients are octogenarians. It has been questioned whether older patients benefit from surgical resection of lung cancer to the same extent as younger patients...
  20. doi request reprint Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance
    Robert O Dillman
    Hoag Cancer Center, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA
    Cancer 115:1840-8. 2009
    ..Identification of > or =12 lymph nodes in resected colon cancer specimens has been endorsed as a quality indicator...
  21. ncbi request reprint Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 22:309-21. 2007
    ..18%; p = 0.159). This treatment approach is feasible, produces minimal toxicity, and is associated with longterm survival in a significant proportion of patients...
  22. ncbi request reprint Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 22:185-93. 2007
    ..PCR is active in CLL/SLL, but appears to be less active and associated with more complications in the community setting, compared to trials with younger, lower risk patients who travel to academic referral centers for treatment...
  23. ncbi request reprint Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia
    Robert O Dillman
    Hoag Cancer Center, 1 Hoag Drive, Building 41, Newport Beach, CA 92660, USA
    Expert Rev Anticancer Ther 4:27-36. 2004
    ....
  24. ncbi request reprint Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group
    Robert O Dillman
    Hoag Cancer Center, Newport Beach CA 92658, USA
    Cancer Biother Radiopharm 18:727-33. 2003
    ..The Cancer Biotherapy Research Group conducted a clinical trial to verify encouraging reports of antitumor activity of autolymphocyte therapy...
  25. ncbi request reprint Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes?
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 20:373-8. 2005
    ..We investigated whether clinical potency of these vaccines could be determined by retrospective correlation between the numbers of cells injected (quantity of tumor antigens) and clinical outcome...
  26. ncbi request reprint Radiologic tests after a new diagnosis of breast cancer
    R O Dillman
    Hoag Cancer Center, Newport Beach, Calif, USA
    Eff Clin Pract 3:1-6. 2000
    ..Radiologic tests may be overused in the staging of newly diagnosed breast cancer...
  27. ncbi request reprint The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Curr Pharm Biotechnol 2:293-300. 2001
    ..In 1997 rituximab (Rituxan), a mouse-human chimeric anti-CD20, became the first MoAb approved by regulatory agencies for the treatment of a human malignancy...
  28. ncbi request reprint 15th Annual Scientific Meeting of the Society for Biological Therapy. 26-29 October 2000, Seattle, Washington, USA
    R O Dillman
    Hoag Cancer Center, One Hoag Drive, Bldg 41, Newport Beach, CA 92658, USA
    Expert Opin Biol Ther 1:129-34. 2001
    ....
  29. ncbi request reprint Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer
    R O Dillman
    Hoag Cancer Center, One Hoag Drive, Building 41, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 16:205-11. 2001
    ..e., autologous vaccine) after resection of primary breast cancer, and/or for the treatment of metastases...
  30. ncbi request reprint Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma
    R O Dillman
    Hoag Cancer Center, One Hoag Drive, Building 41, Newport Beach, CA 92658, USA
    Crit Rev Oncol Hematol 39:115-23. 2001
    ..7 months and 0% for the 13 non-converters (P=0.0026). This treatment approach is feasible, produces minimal toxicity, and is associated with long-term survival in a significant subset of patients...
  31. ncbi request reprint Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma
    R O Dillman
    Hoag Cancer Center, One Hoag Drive, Building 41, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 16:47-54. 2001
    ..We established short-term cultures of autologous tumors from patients with renal carcinoma for use as active specific immunotherapy (i.e., autologous vaccine)...
  32. ncbi request reprint Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11
    R O Dillman
    Patty and George Hoag Cancer Center, One Hoag Drive, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 15:487-94. 2000
    ..The treatment of metastatic melanoma remains unsatisfactory despite encouraging results with biotherapy and combination chemotherapy. Combining these two modalities may improve outcomes for such patients...
  33. ncbi request reprint Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma
    R O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 13:165-76. 1998
    ..Administration of such patient-specific vaccines improves survival for those patients who are NED at the time of vaccination and convert their DTH skin test, compared to those whose DTH test remains negative...
  34. ncbi request reprint The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 14:443-9. 1999
    ..e., autologous vaccine) in such patients after debulking surgery & combination chemotherapy...
  35. ncbi request reprint Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 14:5-10. 1999
    ..It should also prove to be useful in the treatment of subsets of patients with other adenocarcinomas whose tumors over-express HER2...
  36. ncbi request reprint Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 15:161-8. 2000
    ..e., autologous vaccine) in such patients after resection of primary kidney cancer, and/or for the treatment of metastatic cancer...
  37. ncbi request reprint Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Invest 19:833-41. 2001
    ..Monoclonal antibodies have joined interferon-alpha, interleukin-2 (IL-2), and various hematopoietic growth factors as well-established components of biological therapy, the fourth modality of cancer treatment...
  38. ncbi request reprint Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival
    Robert O Dillman
    Hoag Cancer Center, One Hoag Drive, Building 41, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 17:51-66. 2002
    ..We established short-term cultures of pure tumor cells for use as autologous tumor cell vaccines in an effort to study the effects of patients-specific immunotherapy...
  39. ncbi request reprint Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    J Immunother 26:367-73. 2003
    ..Both adjuvants were associated with a 25% to 30% rate of DTH conversion and a 25% 5-year survival rate. Immune recognition of autologous tumor can be induced with this approach...
  40. ncbi request reprint Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma
    Robert O Dillman
    Clinical and Laboratory Cancer Research, Hoag Hospital, Hoag Cancer Center, Newport Beach, CA 92658, USA
    J Clin Oncol 20:3545-57. 2002
  41. ncbi request reprint Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Robert O Dillman
    Clinical and Laboratory Cancer Research, Hoag Cancer Center, Hoag Hospital, Newport Beach, CA 92658, USA
    Curr Hematol Rep 2:30-7. 2003
    ..The product became available for commercial use in April, 2002. Clinical trials will determine how radioimmunotherapy will be integrated into the treatment of lymphoma...
  42. ncbi request reprint Does continuous-infusion interleukin-2 increase survival in metastatic melanoma?
    Robert O Dillman
    Hoag Cancer Center, One Hoag Drive, Building 41, Newport Beach, CA 92658, U S A
    Am J Clin Oncol 26:141-5. 2003
    ..In the absence of a control group, the survival impact of IL-2 has probably been overestimated from single-arm phase II and III trials...
  43. ncbi request reprint 16th Annual Scientific Meeting of the Society for Biological Therapy. 8 - 11 November 2001, Bethesda, Maryland, USA
    Robert O Dillman
    Clinical and Laboratory Cancer Research, Hoag Cancer Center, 1 Hoag Drive, Bldg 41, Newport Beach, CA 92658, USA
    Expert Opin Biol Ther 2:223-7. 2002
    ..The current President is R Dillman MD from the Hoag Cancer Center in Newport Beach, California...
  44. ncbi request reprint A theoretical approach for T-lymphocyte monitoring of autologous cancer vaccine therapy using autologous HLA-class I and HLA-class II constructs
    Patric Schiltz
    Patty and George Hoag Cancer Center, Cell Biology Laboratory, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 19:405-10. 2004
    ..Such an assay should enable monitoring for specific T-lymphocyte antitumor activity in patients being treated with patient specific, autologous, tumor-cell vaccines...
  45. ncbi request reprint Establishment and characterization of a human primary prostate carcinoma cell line, HH870
    Senthamil R Selvan
    Patty and George Hoag Cancer Center, Newport Beach, California 92663, USA
    Prostate 63:91-103. 2005
    ..Most in vitro studies have been carried out using a limited number of human prostate cancer cell lines that are mostly derived from metastatic tumors sites or are immortalized...
  46. ncbi request reprint Serum cytokines in metastatic melanoma patients treated with an autologous tumor vaccine
    Patric M Schiltz
    Hoag Memorial Presbyterian Hospital Cancer Center, Newport Beach, CA, USA
    Cancer Biother Radiopharm 18:879-86. 2003
    ..2 pg/106 cells/mL/96 hours), which would not account for the observed serum levels. In conclusion, the serum cytokine pattern from these patients suggests that the immune system is being modulated prior to and subsequent to vaccination...
  47. doi request reprint Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells
    Patric M Schiltz
    Hoag Cancer Center, Newport Beach, CA, USA
    Cancer Biother Radiopharm 23:214-21. 2008
    ..039). Both LDH and S100B are predictive tumor markers in patients with metastatic melanoma. This is the first study to examine the changes in serum levels of LDH and S100B in response to an autologous tumor-cell vaccine...
  48. doi request reprint Monoclonal antibodies in cancer therapy: 25 years of progress
    Robert K Oldham
    J Clin Oncol 26:1774-7. 2008
  49. ncbi request reprint Human allogeneic and murine xenogeneic dendritic cells are cytotoxic to human tumor cells via two distinct pathways
    Patric M Schiltz
    Hoag Hospital Memorial Presbyterian Hospital Comprehensive Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 22:672-83. 2007
    ..Augmented NO production occurred in DC2.4/U-251 and DC2.4/Jurkat cultures but was not seen in the human DC/U-251 cultures. These studies suggest that DCs possess different mechanisms of tumoricidal activity...
  50. ncbi request reprint Monitoring response to treatment in melanoma patients: potential of a serum glycomic marker
    Senthamil R Selvan
    Cell Biology Laboratory, Hoag Cancer Center, Newport Beach, CA 92663, USA
    Int J Cancer 122:1374-83. 2008
    ..Clinical correlations of sTG indicate that sTG-downregulating therapy may be an effective treatment strategy for melanoma...
  51. ncbi request reprint Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10
    Gamini Soori
    Alegent Bergan Mercy Medical Center, Omaha, NB, USA
    Cancer Biother Radiopharm 17:165-73. 2002
    ..Pilot studies from other investigators have suggested that combining cis-retinoic acid and 5-fluorouracil (5FU) with interleukin-2 (IL-2) and interferon-alpha (IFN) may improve outcomes for such patients...
  52. ncbi request reprint Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan
    Carolyn S Hendrix
    Clin J Oncol Nurs 6:144-8. 2002
    ..Clinical trials of 90Y ibritumomab tiuxetan in patients with NHL have produced promising results. The safe and effective use of radioimmunotherapy requires a multidisciplinary team approach in which nurses play a central role...
  53. ncbi request reprint American Society of Clinical Oncology 41st annual meeting
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Expert Opin Biol Ther 5:1117-27. 2005
    ..This meeting review is organised by biotherapy modality rather than tumour type...
  54. ncbi request reprint Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
    John Nemunaitis
    Mary Crowley Medical Research Center Texas Oncology Professional Association, Dallas, TX, USA
    J Clin Oncol 24:4721-30. 2006
    ..Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition...
  55. ncbi request reprint Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab
    Robert O Dillman
    Hoag Cancer Center, Hoag Hospital, Newport Beach, CA, USA
    Semin Oncol 30:434-47. 2003
    ..Combinations of rituximab with other monoclonal antibodies are currently being tested...
  56. doi request reprint Immunophenotyping of chronic lymphoid leukemias
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA, USA
    J Clin Oncol 26:1193-4. 2008
  57. ncbi request reprint Successful treatment of transitional cell carcinoma of the urethra with chemotherapy
    Louis A VanderMolen
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Invest 20:206-7. 2002